Weight problems and Alzheimer’s medicine pack one-two punch to carry Eli Lilly

Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023. 

George Frey | Bloomberg | Getty Images

Investor optimism for Eli Lilly‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story.

You might also like

Comments are closed.